32nd week of 2011 patent applcation highlights part 40 |
Patent application number | Title | Published |
20110195831 | DUNNAGE CONVERSION MACHINE AND METHOD - A dunnage conversion machine ( | 2011-08-11 |
20110195832 | SEPARATION DISK FOR A CENTRIFUGE ROTOR, AND A DISK PACKAGE - A separating disk for a disk package of a centrifuge rotor has a tapering shape and extends around an axis (x) of rotation, and along a rotary symmetric surface. The separating disk is configured in such a way that it creates an interspace between the separating disk and an adjacent separating disk in the disk package, and comprises first protrusions extending outwardly from the rotary symmetric surface and second protrusions extending inwardly from the rotary symmetric surface. Each first and second protrusion defines a contact zone adapted to abut the adjacent separating disk. The contact zone of the first protrusions is displaced in relation to the contact zone of the second protrusions. The first and second protrusions are provided after each other in the peripheral direction of the separating disk. The tapering shape and the protrusions of the separating disks have been provided though pressing of a blank of a material against a tool part having a shape corresponding to the tapering shape of the protrusions of the pressed separating disk. | 2011-08-11 |
20110195833 | HIGH-REFRACTIVITY LOW-DISPERSION OPTICAL GLASS - The invention provides an environment-friendly optical glass with high refractive index, low dispersion and high light transmittance. The optical glass includes 6%-17% of B | 2011-08-11 |
20110195834 | Wear Resistant Two-Phase Binderless Tungsten Carbide and Method of Making Same - An ultrafine grain two-phase binderless tungsten carbide material is disclosed. The material contains, in weight percent, ditungsten carbide in the range of about 1 to about 10 percent, up to about 1.0 percent vanadium carbide and/or chromium carbide, up to about 0.2 percent cobalt, and the balance tungsten carbide, wherein the wear resistant material has a hardness of at least about 2,900 kg/mm | 2011-08-11 |
20110195835 | DIELECTRIC CERAMIC COMPOSITION AND ELECTRONIC DEVICE - A dielectric ceramic composition comprising a main component expressed by a general formula (Ba | 2011-08-11 |
20110195836 | CATALYTIC NANOTEMPLATES - A catalytic nanotemplate including a freestanding template particle and a director associated with the surface of the freestanding template particle. The free standing template particle may have multiple segments and the director may be associated with one or more of the segments. In instances where multiple segments are present, the segments may be made of different materials or be of the same material in different forms. More than one type of director or no director may be associated with any particular segment. | 2011-08-11 |
20110195837 | Process for the removal of endocrine disrupting compounds - The present invention relates to the removal of endocrine disrupting compounds from an aqueous medium by adding surface-reacted natural calcium carbonate or an aqueous suspension comprising surface-reacted calcium carbonate and having a pH greater than 6.0 measured at 20° C., to the medium, wherein the surface-reacted calcium carbonate is a reaction product of natural calcium carbonate with carbon dioxide and one or more acids, the use of the surface-reacted natural calcium carbonate for the removal of endocrine disrupting compounds, as well as to a combination of a surface-reacted natural calcium carbonate and activated carbon for the removal of endocrine disrupting compounds. | 2011-08-11 |
20110195838 | ALUMINUM TITANATE CERAMIC FORMING BATCH MIXTURES AND GREEN BODIES INCLUDING PORE FORMER COMBINATIONS AND METHODS OF MANUFACTURING AND FIRING SAME - A ceramic forming batch mixture including inorganic batch materials, such as sources of alumina, titania, and silica, a pore former combination including first and second pore formers with different compositions; an organic binder; and a solvent. Also disclosed is a method for producing a ceramic article involving mixing the inorganic batch materials with the pore former combination having first and second pore formers of different composition, adding an organic binder and a solvent, forming a green body; and firing the green body. A green body having a combination of first and second pore formers with different compositions is disclosed, as are several methods for firing to produce ceramic articles such as aluminum titanate. | 2011-08-11 |
20110195839 | Liquid Aqueous Crop Protection Formulations - The present invention relates to a novel liquid aqueous plant protection formulation which comprises
| 2011-08-11 |
20110195840 | Herbicide combination - The present invention relates to a herbicide combination comprising components (A) and (B), where
| 2011-08-11 |
20110195841 | USE OF AZOLES FOR INCREASING THE ABIOTIC STRESS RESISTANCE OF PLANTS OR PLANT PARTS - The invention relates to the use of at least one compound, selected from the group consisting of tebuconazole, epoxiconazole, metconazole, cyproconazole, prothioconazole and any mixtures thereof, for increasing the resistance of plants to abiotic stress factors. | 2011-08-11 |
20110195842 | 2,4,6-Phenyl-Substituted Cyclic Ketoenols - The invention relates to novel 2,4,6-phenyl-substituted cyclic ketoenols of the formula (I), | 2011-08-11 |
20110195843 | Plants with Increased Yield (LT) - A method for producing a plant with increased yield as compared to a corresponding wild type plant comprising at least the following step: increasing or generating in a plant or a part thereof one or more activities selected from the group consisting of 3-phosphoglycerate dehydrogenase, Adenylate kinase, B2758-protein, Cyclic nucleotide phosphodiesterase, cysteine synthase, Exopolyphosphatase, geranylgeranyl reductase, Mating hormone A-factor precursor, mitochondrial succinate-fumarate transporter, modification methylase HemK family protein, Myo-inositol transporter, oxidoreductase subunit, peptidy-prolyl-cis-trans-isomerase, protein kinase, Ribose-5-phosphate isomerase, slr1293-protein, YDR049W-protein, YJL181W-protein, and YPL109C-protein-activity. | 2011-08-11 |
20110195844 | PROCESS FOR SOLUBILIZING HYDROPHOBIC ACTIVE INGREDIENTS IN AQUEOUS MEDIUM - A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from
| 2011-08-11 |
20110195845 | Constructs for Expressing Herbicide Tolerance Genes, Related Plants, and Related Trait Combinations - Constructs for expressing herbicide tolerance genes, related plants, and related trait combinations, said constructs comprise a gene referred to herein as DSM-2 identified in | 2011-08-11 |
20110195846 | Liquid Pyraclostrobin-Containing Crop Protection Formulations - The present invention relates to a novel liquid formulation for crop protection which comprises a) pyraclostrobin; b) at least one organic solvent S1 with a water solubility of less than 2 g/l at 20° C.; c) at least one organic solvent S2 with a water solubility of at least 2 g/l at 20° C., where S2 comprises at least one solvent S2.1 with a water solubility of more than 200 g/l at 20° C. and optionally at least one solvent S2.2 with a water solubility of 2 to 200 g/l at 20° C.; d) at least one anionic surface-active substance SA1; e) at least one nonionic surface-active substance SA2; and f) water. The invention also relates to the use of the crop protection formulation for treatment of plants and seed, and to corresponding methods. | 2011-08-11 |
20110195847 | METHODS TO TREAT SOLID TUMORS - A high throughput method for identifying promoters differentially activated in solid tumors as compared to normal tissues is described. The promoters so identified may be used to drive production of RNA's or proteins useful in treating solid tumors including toxic RNA's or proteins and other therapeutic RNA's or proteins. | 2011-08-11 |
20110195848 | GENE EXPRESSION AND BREAST CANCER - This invention provides methods and reagents for determining breast cancer patient prognosis and/or diagnosis of tumor aggressiveness, disease-free survival times and reduced patient disease-free survival metrics. | 2011-08-11 |
20110195849 | METHODS AND COMPOSITIONS FOR IDENTIFYING INHIBITORS OF MUTS-alpha OR MUTS-beta INTERACTION WITH MUTL-alpha - Disclosed are methods and kits for screening potential inhibitors of MutSβ by screening agents for the ability to selectively inhibit interaction between MutSβ and MutLα. Also disclosed are kits for performing the methods of the invention. | 2011-08-11 |
20110195850 | COMPACT NANOFABRICATION APPARATUS - An apparatus for use in fabricating structures and depositing materials from tips to surfaces for patterning in direct-write mode, providing ability to travel macroscopic distances and yet provide for nanoscale patterning. Useful in small scale fabrication and nanolithography. The instrument can be compact and used on a laboratory bench or desktop. An apparatus comprising: at least one multi-axis assembly comprising a plurality of nanopositioning stages, at least one pen assembly, wherein the pen assembly and the multi-axis assembly are adapted for delivery of material from the pen assembly to a substrate which is positioned by the multi-axis assembly, at least one viewing assembly, at least one controller. Nanopositioning by piezoelectric methods and devices and motors is particularly useful. The apparatus can include integrated environmental chambers and housings, as well as ink reservoirs for materials to be delivered. The viewing assembly can be a microscope with a long working distance. Particularly useful for fabrication of bioarrays or microarrays. The multi-axis assembly can be a five-axis assembly. Software can facilitate efficient usage. | 2011-08-11 |
20110195851 | SYSTEMS AND METHODS FOR DETERMINING THERAPEUTIC POTENTIAL - Systems and methods for determining therapeutic potential. In at least one embodiment of a system of the present disclosure, the system comprises a detection platform, a computer processor and a database. The processor, in at least one embodiment of a method of the present disclosure, has and executes a software program operational to determine a binding characteristic of the detection agent and a stabilized diagnostic marker in each of the plurality of detection sites on the platform, compare the binding characteristic, and determining the stabilizing agent with the greatest effect on the binding characteristic between the detection agent and the diagnostic marker. Further, at least one embodiment of a system for determining the therapeutic potential of a therapeutic compound of the present disclosure is able to generate a binding record using the compared binding characteristics, and deliver the binding record to a recipient. | 2011-08-11 |
20110195852 | METHODS FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN SOLUTION - Disclosed is a method for measuring the concentration of an analyte or analytes in a solution. Although the methods can be conducted using a number of different assay formats, in one embodiment, the assays are conducted in reaction vessels defined, at least in part, by the distal ends of fiber optic strands. | 2011-08-11 |
20110195853 | Array with Extended Dynamic Range and Associated Method - A system and method of quantitating the concentration of a molecule of interest in one embodiment includes establishing a plurality of test environments at a plurality of test sites, each of the plurality of test environments associated with one of a plurality of response curves, each of the plurality of response curves different from the other of the plurality of response curves, storing a combined response curve resulting from a summation of the plurality of response curves, exposing the plurality of test sites to a sample having a concentration of a molecule of interest, obtaining a plurality of quantitation signals, each of the plurality of quantitation signals associated with one of the plurality of test sites, associating a summation of the plurality of quantitation signals with the stored combined response curve, and generating a signal related to the concentration of the molecule of interest based upon the association. | 2011-08-11 |
20110195854 | DETECTING AND MONITORING INFLAMMATORY NEUROPATHY - The invention relates to detection and/or monitoring of inflammatory neuropathy using markers that specifically indicate the presence of inflammatory neuropathy, for example, allograft inflammatory factor 1 (AIF1), lymphatic hyaluronan receptor (LYVE-1), FYN binding protein (FYB), myeloid/lymphoid or mixed-lineage leukemia, translocated to, 3 (MLLT3), purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) or a combination thereof. According to the invention, skin biopsies can be used for assessing the expression of these markers. | 2011-08-11 |
20110195855 | SYSTEMS AND METHODS FOR IMPROVING BIOMARKER AVAILABILITY - Systems and Methods for Improving Biomarker Availability. In at least one embodiment of a computer-implemented method of improving diagnostic marker availability, the method comprises the steps of introducing a predetermined diagnostic marker for cancer into a plurality of detection sites of a detection platform, introducing a stabilization agent into each of the plurality of detection sites containing the predetermined diagnostic marker for cancer, introducing a detection agent into each of the plurality of detection sites having a stabilized diagnostic agent, determining a binding characteristic of the detection agent and the stabilized diagnostic agent in each of the plurality of detection sites with a processor, and computationally comparing the binding characteristic among each of the plurality of detection sites with the processor, wherein the comparison of binding characteristics is capable of determining the stabilizing agent with the greater effect on the binding characteristic between the detection agent and the diagnostic agent. | 2011-08-11 |
20110195856 | METHODS OF DETERMINING STABILIZATION COMPOUNDS FOR PREDICTIVE BIOMARKERS - Methods of determining stabilization compounds for predictive biomarkers. According to at least one embodiment of a method of the present disclosure, the method comprises introducing a diagnostic marker and a stabilization agent to a detection platform, mixing the diagnostic marker and stabilization agent, and determining their binding characteristics. | 2011-08-11 |
20110195857 | SYSTEMS FOR ANALYZING STABILIZED BIOMARKERS - Systems for analyzing stabilized biomarkers. In at least one embodiment of a system for the detection of a diagnostic marker of the present disclosure, the system comprises a detection platform comprising a plurality of detection wells housed in a solid matrix, wherein the detection wells contain a plurality of diagnostic markers and at least one competitor molecule, wherein the plurality of diagnostic markers and at least one control molecule are each bound to a paramagnetic particle. An embodiment of the system of the present disclosure further comprises a detection system capable of receiving the detection platform, exerting a magnetic field upon a surface of the detection platform, and determining at least one characteristic of the diagnostic marker. | 2011-08-11 |
20110195858 | SYSTEMS AND METHODS OF ANALYZING BIOMARKER LEVELS - Systems and methods of analyzing biomarker levels. In at least one embodiment of a method of analyzing biomarker levels, the method comprises the steps of combining a body fluid comprising a diagnostic marker with a stabilization agent for an incubation period, introducing the stabilized body fluid into a detection platform, combining a detection agent with the stabilized body fluid, determining an interaction characteristic of the detection agent and the diagnostic marker of the stabilized body fluid using a detection device in communication with a processor, comparing the interaction characteristic with a plurality of indexed interaction records contained on a database in communication with the processor to determine an identity and concentration of the detection marker, generating a report of the identity and concentration of the detection marker in the body fluid, and delivering the report to a recipient. | 2011-08-11 |
20110195859 | SYSTEMS AND METHODS FOR THE DETECTION OF BIOMARKERS - System and methods for the detection of biomarkers. In at least one embodiment of a system for the detection of a diagnostic marker in a body fluid of the present disclosure, the system comprises a diagnostic device comprising a plurality of test wells, wherein each test well is capable of containing at least one detection agent, a detection device capable of interacting with the diagnostic device, wherein the detection device is capable of detecting an interaction between the at least one detection agent and a diagnostic marker in at least one of the plurality of test wells, and a stabilization agent contained within at least one of the plurality of test wells, the stabilization agent capable of completely or substantially preventing the degradation or inactivation of the detection agent or the diagnostic marker. | 2011-08-11 |
20110195860 | FIBROUS ASSEMBLIES FOR ANTIBODY PRESENTATION, AND MULTIPLEXED ANTIGENIC ANALYSIS USING SAME - Biofunctionalized fibers including a fiber platform and a histidine-tagged protein and, optionally, an antibody. Chitosan is a fiber useful as the fiber platform. The fiber platform may be treated with nickel or may be directly linked to the histidine-tagged protein e.g., histidine-tagged streptococcal IgG-binding protein, protein G, protein G3T, GFP or RFP. The resulting biofunctionalized fibers can be assembled into protein fiber assemblies by a variety of biofabrication methods. The fiber assemblies, e.g., in the form of woven fabrics, are useful for (i) antigen capture; (ii) immunoanalysis, and/or (iii) multiplexed analysis. In one fabrication, each fiber of a fiber assembly presents a specific antibody, and mixing and matching of fibers, for example by weaving of fabrics from various antibody-presenting fibers, allows for multiple antigens to be captured simultaneously for multiplexed analysis. | 2011-08-11 |
20110195861 | METHOD OF DETECTING AUTO-ANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS, A PEPTIDE AND AN ASSAY KIT - A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against | 2011-08-11 |
20110195862 | DEVICES, METHODS AND SYSTEMS FOR TARGET DETECTION - Polymer arrays suitable to perform quantitative and qualitative detection as well as sorting of a target molecules and related devices methods and systems. | 2011-08-11 |
20110195863 | Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits - The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K | 2011-08-11 |
20110195864 | Assays for determining telomere length and repeated sequence copy number - Methods of detecting copy number of a repeated sequence element, including methods of determining telomere length, are provided. The methods can be multiplexed for detection of repeated sequence element copy number on two or more nucleic acid targets simultaneously. Compositions, kits, and systems related to the methods are also described. | 2011-08-11 |
20110195865 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS - The invention enables high-throughput screening of compounds in living systems to detect unanticipated or unintended biological actions. The invention also allows for screening, detection, and confirmation of new indications for approved drugs. Screening and detection of toxic effects of compounds also can be achieved by using the methods of the invention. The methods comprise administering isotope-labeled substrates to a living system so that the label is incorporated into molecules in a manner that reveals flux rates through metabolic pathways thought to be involved in a disease. Comparisons between living systems exposed to compounds and living systems not so exposed reveals the effects of the compounds on the flux rates through the metabolic pathways. Combinations or mixtures of compounds can be systematically screened to detect unanticipated or unintended biological actions, including synergistic actions, in the same manner. | 2011-08-11 |
20110195866 | AUTOMATED MULTI-STATION SMALL OBJECT ANALYSIS - The present disclosure provides systems and methods for analyzing a plurality of samples of small objects. In various other embodiments, the system ( | 2011-08-11 |
20110195867 | METHOD OF ANALYZING PROTEIN MICROSTRUCTURE AND STRUCTURE FOR THE SAME - A method of analyzing a protein structure is provided. The method includes immobilizing capture molecules to a substrate, the capture molecules being able to capture target molecules regardless of the microstructure of the target molecules, forming a first complex by binding the capture molecules to the target molecules, forming a plurality of second complexes by binding the first complex to one of plural kinds of probe molecules, measuring a binding affinity between the first complex and the probe molecules by performing a color development to the plurality of second complexes, and confirming the target molecules by comparing the measured binding affinity with conventional data of binding affinities. Therefore, the method may be useful in analyzing the microstructure of the target protein simply using relatively simple analytical instruments or reagents without use of the expensive instruments or skilled techniques. | 2011-08-11 |
20110195868 | METHODS AND COMPOSITIONS FOR GENETICALLY DETECTING IMPROVED MILK PRODUCTION TRAITS IN CATTLE - An isolated nucleic acid molecule comprising a polymorphic site selected from the group consisting of positions 164, 269, 284, 407 and 989 of SEQ ID NO: 1, an array or a kit comprising the same. Also provided are a method for detecting single nucleotide polymorphism (SNP) in bovine proteinase inhibitor (PI) gene, a method for haplotyping a bovine cell, a method for progeny testing of cattle based on said haplotyping, a method for selectively breeding of cattle based on haplotyping a parent animal. The present invention further provides a method for testing a dairy cattle for its milk production trait, comprising haplotyping its cells, wherein a cattle having haplotypes 1, 3, 4 or 5 indicates that the cattle has desirable milk production trait. Haplotype 1 indicates that the cattle has the most desirable milk production trait. | 2011-08-11 |
20110195869 | APPARATUS FOR SYNTHESIZING MICROARRAY PROBE, AND METHOD OF SYNTHESIZING MICROARRAY PROBE USING THE APPARATUS - An apparatus for synthesizing a microarray probe, the apparatus including a capillary nozzle, and a method of synthesizing a microarray probe by using the apparatus. The probe is efficiently synthesized by using the apparatus. | 2011-08-11 |
20110195870 | Method of combing a nucleic acid - Elongated molecules are stretched across a substrate by controlled fluid flow. | 2011-08-11 |
20110195871 | SYSTEMS AND METHODS OF SCREENING BIOMARKERS IN BODILY FLUIDS - Systems and methods of screening biomarkers in bodily fluids. According to at least one embodiment of the system for analyzing stabilizing agents of the present disclosure, the system comprises a detection platform comprising a plurality of detection sites each capable of receiving a diagnostic marker, a stabilization agent, and a detection agent. The system, in at least one embodiment, further comprises a detection device capable of determining a binding characteristic between the detection agent and the diagnostic marker in the detection sites. Further, the system may also be able to compare the binding characteristic among a plurality of detection markers to order the level of effect of the stabilizing agents assayed on the binding characteristic between the detection agent and the diagnostic agent. | 2011-08-11 |
20110195872 | DEVICES AND SYSTEMS FOR BIOMARKER DETECTION - Devices and systems for biomarker detection . In at least one embodiment of a diagnostic testing device of the present disclosure, the device comprises a fluid collector to collect a body fluid, and a housing, to test and retain the body fluid. The housing, in at least one embodiment, comprises a collection chamber, having an open end, to receive the fluid collector and contain a stabilization reagent, at least one membrane test strip, to indicate the presence or absence of at least one diagnostic marker, and an immunoassay-based fingerprint acquisition pad in fluid communication with the collection chamber. | 2011-08-11 |
20110195873 | SYSTEMS AND METHODS FOR THE DETECTION OF BIOMARKERS - Systems and methods for the detection of biomarkers. In at least one embodiment of a microarray system of the present disclosure, the microarray system comprises a microarray product comprising at least 100 diagnostic markers/cm | 2011-08-11 |
20110195874 | SYSTEMS AND METHODS FOR BIOMARKER ANALYSIS - Systems and methods of biomarker analysis. In at least one embodiment of a system for determining the therapeutic potential of a therapeutic compound the present disclosure, the system comprises a detection platform, a computer database capable of receiving a plurality of binding characteristics, a processor operably coupled to the computer database and the detection platform. In at least one embodiment, the processor has and executes a software program operational to determine a binding characteristic of the detection agent and a stabilized diagnostic agent in each of the plurality of detection sites, compare the binding characteristic among each of the plurality of detection sites, wherein the comparison of binding characteristics is capable of determining the stabilizing agent with the greatest effect on the binding characteristic between the detection agent and the diagnostic agent, generate a binding record using the compared binding characteristics, and deliver the binding record to a recipient. | 2011-08-11 |
20110195875 | ENCAPSULATED REACTANT AND PROCESS - An encapsulated reactant(s) having at least one encapsulant and at least one reactant. An outermost encapsulant is substantially nonreacting, impermeable and nondissolving with water. The reactant(s) contribute to at least one reaction with contaminants in environmental media rendering the environmental media less harmless. Processes for using the encapsulated reactant in environmental media is also hereby claimed. | 2011-08-11 |
20110195876 | Olefinically Unsaturated Phosphonate Compounds, Polymers Made Therefrom And Their Use - This invention relates to compounds of formulae (1a) and (1b) | 2011-08-11 |
20110195877 | CRYSTALLINE CERAMIC PARTICLES - Crystalline ceramic particles including at least 90 percent by weight Al | 2011-08-11 |
20110195878 | METHOD FOR IMPROVING THE FUEL EFFICIENCY OF ENGINE OIL COMPOSITIONS FOR LARGE LOW AND MEDIUM SPEED ENGINES BY REDUCING THE TRACTION COEFFICIENT - The present invention is directed to a method for improving the fuel efficiency of low and medium speed engine oil compositions by reducing the traction coefficient of the oil by formulating the oil using at least two base stocks of different kinematic viscosity wherein the differences in kinematic viscosity between the base stocks is at least 30 mm | 2011-08-11 |
20110195879 | INERT WEAR RESISTANT FLUOROPOLYMER-BASED SOLID LUBRICANTS, METHODS OF MAKING AND METHODS OF USE - The present disclosure includes fluoropolymer-based materials, methods of making fluoropolymer-based materials, methods of using fluoropolymer-based materials, and the like. | 2011-08-11 |
20110195880 | GREASE COMPOSITION - A grease composition for use in resin lubrication wherein at least one amine salt of an unsaturated or saturated fatty acid is incorporated in a grease base material which includes a base oil and a thickener, preferably wherein at least one fatty acid amine salt of the following general formula (1) is incorporated: RCOO | 2011-08-11 |
20110195881 | CONVERSION OF VEGETABLE OILS TO BASE OILS AND TRANSPORTATION FUELS - The present invention is directed to methods (processes) and systems for processing triglyceride-containing, biologically-derived oils to provide for base oils and transportation fuels, wherein partial oligomerization of fatty acids contained therein provide for an oligomerized mixture from which the base oils and transportation fuels can be extracted. Such methods and systems can involve an initial hydrotreating step or a direct isomerization of the oligomerized mixture. | 2011-08-11 |
20110195882 | METHOD FOR IMPROVING THE FUEL EFFICIENCY OF ENGINE OIL COMPOSITIONS FOR LARGE LOW, MEDIUM AND HIGH SPEED ENGINES BY REDUCING THE TRACTION COEFFICIENT - The present invention is directed to a method for improving the fuel efficiency of engine oil compositions for large low, medium and high speed engines by reducing the traction coefficient of the oil by formulating the oil using at least two base stocks of different kinematic viscosity wherein the differences in kinematic viscosity between the base stocks is at least 30 mm | 2011-08-11 |
20110195883 | METHOD FOR IMPROVING THE FUEL EFFICIENCY OF ENGINE OIL COMPOSITIONS FOR LARGE LOW AND MEDIUM SPEED GAS ENGINES BY REDUCING THE TRACTION COEFFICIENT - The present invention is directed to a method for improving the fuel efficiency of large engine oil compositions by reducing the traction coefficient of the oil by formulating the oil using at least two base stocks of different kinematic viscosity wherein the differences in kinematic viscosity between the base stocks is at least 32 mm | 2011-08-11 |
20110195884 | METHOD FOR IMPROVING THE FUEL EFFICIENCY OF ENGINE OIL COMPOSITIONS FOR LARGE LOW AND MEDIUM SPEED ENGINES BY REDUCING THE TRACTION COEFFICIENT - The present invention is directed to a method for improving the fuel efficiency of engine oil compositions by reducing the traction coefficient of the oil by formulating the oil using a blend of one or more first base stock(s) selected from Group II base stock, Group III base stock and Group IV base stock and a second base stock selected from polyisobutylene (PIB) and, preferably, additized with a detergent. | 2011-08-11 |
20110195885 | Vegetable oil-based hydraulic fluid and transmission fluid - The invention relates to using vegetable oil having a natural viscosity index (VI) of greater or equal to 200 as a pressure medium in hydraulic systems and as a transmission fluid. The vegetable oil has a portion of monounsaturated fatty acids of at least 80%, a portion of double unsaturated fatty acids of 1-10% at maximum, and a portion of triple unsaturated fatty acids of less than 1%, preferably less than 0.1%. Part of the vegetable oil can be used in the form of an unsaturated ester of the vegetable oil. The vegetable oil can also contain an additive in a portion of 2-5% by weight selected from anti-oxidants, copper deactivators, anti-corrosion agents, wear protection agents and anti-foaming agents. The shear stability of the vegetable oil used according to the invention equals 0.7% or less, measured over 20 hours of use. | 2011-08-11 |
20110195886 | USE OF AN OLIGOMER-BASED ADDITIVE FOR STABILIZING A LUBRICATING COMPOSITION FOR A CONVEYOR CHAIN - The use of an additive including a mixture of oligomers that is produced from the reaction of aromatic amines chosen from:
| 2011-08-11 |
20110195887 | AQUEOUS ACIDIC FORMULATIONS FOR COPPER OXIDE ETCH RESIDUE REMOVAL AND PREVENTION OF COPPER ELECTRODEPOSITION - A highly aqueous acidic cleaning composition for copper oxide etch removal from Cu-dual damascene microelectronic structures and wherein that composition prevents or substantially eliminates copper redeposition on the Cu-dual damascene microelectronic structure. | 2011-08-11 |
20110195888 | POST-CMP TREATING LIQUID AND MANUFACTURING METHOD OF SEMICONDUCTOR DEVICE USING THE SAME - Post-CMP treating liquids are provided, one of which includes water, an amphoteric surfactant, an anionic surfactant, a complexing agent, resin particles having carboxylic group and sulfonyl group on their surfaces, a primary particle diameter thereof ranging from 10 to 60 nm, and tetramethyl ammonium hydroxide. Another includes water, polyphenol, an anionic surfactant, ethylene diamine tetraacetic acid, resin particles having carboxylic group and sulfonyl group on their surfaces, a primary particle diameter thereof ranging from 10 to 60 nm, and tetramethyl ammonium hydroxide. Both of the treating liquids have a pH ranging from 4 to 9, and exhibit a polishing rate both of an insulating film and a conductive film at a rate of 10 nm/min or less. | 2011-08-11 |
20110195889 | COPOLYMER FOR SURFACE PROCESSING OR MODIFICATION - The invention relates to a composition for processing and/or modifying surfaces, particularly hard surfaces or textile surfaces. The composition includes a synthetic copolymer including cationic units and other units | 2011-08-11 |
20110195890 | CLEANING COMPOSITIONS - The subject of the invention is a composition comprising (i) from 10% to 25% by weight of 1,1,1,3,3-pentafluorobutane, preferably 16% to 24% by weight of 1,1,1,3,3-pentafluorobutane; (ii) from 62% to 70% by weight of trans-dichloroethylene, preferably from 63% to 68% by weight of trans-dichloroethylene, (iii) from 10% to 21% by weight of nonafluoromethoxybutane, preferably from 11% to 17% by weight of nonafluoromethoxybutane; and; (iv) from 1% to 4% by weight of nonafluoroethoxybutane, preferably from 2% to 4% by weight of nonafluoroethoxybutane. The subject matter of the invention is also to the use of said composition as a cleaning, solvent, degreasing, defluxing or drying agent. | 2011-08-11 |
20110195891 | FERMENTED MILK OR VEGETABLE PROTEINS COMPRISING RECEPTOR LIGAND AND USES THEREOF - The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal. | 2011-08-11 |
20110195892 | Artifical Pulmonary Surfactant Compositions - The peptides according to the present invention have a high surfactant activity, but no or little hemolytic activity and comprises D-amino acid and acids at a rate of approximately 5% to 40% of the structuring amino acids. The pulmonary surfactant composition of the present invention comprises a mixture of the peptide with a natural lecithin such as soy lecithin and so on Therefore, the pulmonary surfactant composition can be expected to be developed as a pulmonary surfactant without using any animal-derived substance, which has a high surfactant activity and can be produced at reasonable costs and on a large scale. | 2011-08-11 |
20110195893 | USE OF APOLIPOPROTEINS TO DECREASE INFLAMMATION - The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory response due to an autoimmune disease or an injury). | 2011-08-11 |
20110195894 | CD5 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS AND INFLAMMATORY PROCESSES OF FUNGAL ORIGIN - The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin. | 2011-08-11 |
20110195895 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2011-08-11 |
20110195896 | ISOFORM-SPECIFIC INSULIN ANALOGUES - A method treating a mammal by administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof where the insulin analogue displays more than twofold greater binding affinity to insulin receptor isoform A (IR-A) than insulin receptor isoform B (IR-B). The insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A-chain sequence or an analogue thereof and an insulin B-chain sequence or an analogue thereof connected by a polypeptide of 4-13 amino acids. A single-chain insulin analogue may display greater in vitro insulin receptor binding to IR-A but lower binding to IR-B than normal insulin while displaying less than or equal binding to IGFR than normal insulin. | 2011-08-11 |
20110195897 | GLYCOSYLATED GLP-1 PEPTIDE - Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers. | 2011-08-11 |
20110195898 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS - Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists. | 2011-08-11 |
20110195899 | Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid - Formulations of modified human growth hormone polypeptides are provided. | 2011-08-11 |
20110195900 | PEPTIDIC PTH RECEPTOR AGONISTS - Novel peptidic pth receptor agonists and methods of using the same are provided. | 2011-08-11 |
20110195901 | ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 2011-08-11 |
20110195902 | Fusion Protein Composed of Matrix Metalloproteinase-2 Inhibitor Peptide Derived From Amyloid-B Precursor Protein and Tissue Inhibitor of Metalloproteinase-2 - The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic for cardiovascular diseases, and a matrix metal loproteinase-2 inhibitor, each of which comprises the fusion molecule. | 2011-08-11 |
20110195903 | METHODS AND COMPOSITIONS FOR DETECTING RECESSIVE FAMILIAL FSGS AND USES THEREOF - Described herein are genomic and proteomic biomarkers for the diagnosis of FSGS. Methods for diagnosing FSGS or a predisposition to develop FSGS using the described biomarkers are also provided. Further provided are methods for choosing a course of treatment or administering treatment based on a diagnosis of FSGS using the disclosed biomarkers. | 2011-08-11 |
20110195904 | METHODS OF TREATMENT USING EXENDIN PEPTIDES OR GLP-1 PEPTIDES - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 2011-08-11 |
20110195905 | APLS FOR TREATING ARTHRITIS - One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient. | 2011-08-11 |
20110195906 | OSTEOGENIC SYNTHETIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND MEDIUM CONTAINING THE SAME - Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis. | 2011-08-11 |
20110195907 | AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF - The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention. | 2011-08-11 |
20110195908 | PROSAPOSIN AS A NEUROTROPHIC FACTOR - Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons. | 2011-08-11 |
20110195909 | NOVEL X-CONOTOXIN PEPTIDES (-II) - An isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not Mr1A, Mr1B, Mar2, CMrV1A, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof. | 2011-08-11 |
20110195910 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER - The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of γ-tocotrienol or δ-tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia, colon cancer, liver cancer, bladder cancer, breast cancer and lung cancer. The present invention is further directed to a composition comprising at least one of γ-tocotrienol or δ-tocotrienol and Docetaxel and/or Dacarbazine, and to a method of inhibiting or arresting or reversing of cancer by administering a composition comprising at least one of γ-tocotrienol or δ-tocotrienol together with Docetaxel and/or Dacarbazine. The present invention is also directed to methods of manufacturing those compositions. | 2011-08-11 |
20110195911 | SYNTHETIC ANALOGS OF THE JUXTAMEMBRANE DOMAIN OF IGF1R AND USES THEREOF - A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods. | 2011-08-11 |
20110195912 | Oligomer-Protease Inhibitor Conjugates - Provided are small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water soluble oligomer. | 2011-08-11 |
20110195913 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer - Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one active principle are provided. | 2011-08-11 |
20110195914 | MACROCYCLIC ANTIPROLIFERATION AGENTS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders. | 2011-08-11 |
20110195915 | Method of inhibiting prostate cancer cell proliferation - The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA | 2011-08-11 |
20110195916 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 2011-08-11 |
20110195917 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE - The invention relates to a pharmaceutical composition according to the claim | 2011-08-11 |
20110195918 | METHOD FOR PRODUCING PECTIN HYDROLYSIS PRODUCTS - Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described. | 2011-08-11 |
20110195919 | COMBINATION THERAPY FOR ACNE VULGARIS COMPRISING ADMINISTRATION OF ADAPALENE 0.3% GEL AND CLINDAMYCIN/BENZOYL PEROXIDE GEL - A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®. | 2011-08-11 |
20110195920 | BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES - Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described. | 2011-08-11 |
20110195921 | ELIMINATION OF A CONTAMINATING NON-HUMAN SIALIC ACID BY METABOLIC COMPETITION - The disclosure provides a method of reducing or eliminating Neu5Gc in a cell culture or in a human subject. The method includes flooding the system with the human sialic acid i\7-acetylneuraminic acid (Neu5Ac) in glycosidically-bound or free form, or its precursor N-acetylmannosamine (ManNAc) in an amount sufficient to metabolically compete out the Neu5Gc, either as it enters the cells for the first time or when it recycles from break-down of preexisting cellular molecules. Additionally, Neu5Ac feeding results in reduction of Neu5Gc expression even in some animal cells capable of Neu5Gc production. | 2011-08-11 |
20110195922 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 2011-08-11 |
20110195923 | Methods for Predicting the Response to Anti-Cancer Treatment with an Agonist of TLR7 or an Agonist of TLR8 - The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient. | 2011-08-11 |
20110195924 | Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products - A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, and/or other analogs, or salts, hydrates, or solvates thereof. In addition, provided herein are methods of treating a cancer comprising administering to a mammal a therapeutically effective amount of cromolyn, C5, and/or other analogs, or salts, hydrates, or solvates thereof. | 2011-08-11 |
20110195925 | Sterile Hyaluronic Acid Solutions - A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution. | 2011-08-11 |
20110195926 | PURIFIED BETA GLUCAN COMPOSITION - The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases. | 2011-08-11 |
20110195927 | Compositions Comprising Polymers Having Amino Sugar Units and Methods of Making and Using Same - Compositions comprise a polymer having units of an amino sugar, a polyol other than sorbitol, and boric acid, a salt thereof, or a combination thereof. Such compositions remain for an extended period in the eye and can be used for relief, treatment, or control of a condition of dry eye or discomfort resulting therefrom. | 2011-08-11 |
20110195928 | Administration of Copper to an Animal - The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer. | 2011-08-11 |
20110195929 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS - Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described. | 2011-08-11 |
20110195930 | PYRIDINE DERIVATIVE OR ITS SALT, PESTICIDE CONTAINING IT AND PROCESS FOR ITS PRODUCTION - To provide a novel pesticide. The present invention provides a pesticide which contains, as an active ingredient, novel pyridine derivative represented by the formula (I) or its salt: wherein R | 2011-08-11 |